Dog Cancer News is a free newsletter that contains useful information designed to help your dog with cancer. To sign up, please visit http://bit.ly/dcn_yt
--
For many years, DNA sequencing has been a first line option for diagnosing and treating many human cancers, in a treatment that is often referred to as, targeted therapy. Targeted therapy works by directly inhibiting the growth and replication of the cancer cells in certain types of tumors, and because of its targeted action it has shown high rates of tumor responsiveness in people. So, what happens when you take this science and apply it to dogs? Well, essentially the same thing, which is exciting and is exactly what we are talking about this week with Ben Lewis, the co-founder of FidoCure.
Ben Lewis, the co-founder of FidoCure gives our listeners a deep lesson about genomic sequencing, as it relates to cancer causing DNA mutations. He shares the science behind FidoCure, the types of dog tumors that they’ve had the most success with, as well as how all this biotechnology and science could really help improve the standard of care and the prognosis of many types of cancers in humans and their dogs.
--
For episode notes, resources, guest bios and a transcript, please visit https://dogcanceranswers.com/what-is-fidocure-ben-lewis-deep-dive/
